All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CYAD-211,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: CYAD-211
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
The presentations will focus on the company’s anti-BCMA allogeneic CAR T candidate, CYAD-211, and autologous NKG2D receptor-based CAR T candidates CYAD-01 and CYAD-02.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CYAD-101
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020
Details:
Two patients achieved a confirmed partial response and nine patients achieved stable disease, leading to a disease control rate of 73% following tretment with CYAD-101.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CYAD-02
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2020
Details:
Data from this study will provide insights into the pharmacokinetic profile of the four formulations and provide guidance on final formulation selection and dosing for future clinical trials.